[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603105":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":42,"responsibleParty":59,"collaborators":63,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":36,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":36,"enrollmentInfo":76,"targetDuration":36,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":45,"whyStopped":36,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"0mm PTV","EXPERIMENTAL","0mm uncertainty margin",[13],"Radiation: Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV",{"label":15,"type":16,"description":17,"interventionNames":18},"1mm PTV","ACTIVE_COMPARATOR","1mm uncertainty margin",[13],[20],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":24},"RADIATION","Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV",[9,15],[25,26],"SRS","SRT",[28],{"name":29,"affiliation":30,"role":31},"Ayal A Aizer, MD, MHS","Dana-Farber\u002FBrigham and Women's Cancer Center","PRINCIPAL_INVESTIGATOR",[33,38],{"name":29,"role":34,"phone":35,"phoneExt":36,"email":37},"CONTACT","(617) 732-7560",null,"aaaizer@partners.org",{"name":39,"role":34,"phone":40,"phoneExt":36,"email":41},"Ivy B Ricca, BA","(617) 582-8927","iricca@mgb.org",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Brigham and Women's Hospital \u002F Dana-Farber Cancer Institute","RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-71.05977,42.35843,{"lat":55,"lon":54},[58],{"name":29,"role":34,"phone":35,"phoneExt":36,"email":37},{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"SPONSOR_INVESTIGATOR","Ayal A. Aizer, MD","Director, Central Nervous System Radiation Oncology; Associate Professor, Harvard Medical School",[64],{"name":65,"class":66},"Varian, a Siemens Healthineers Company","INDUSTRY","100603105","phase-2-stereotactic-radiation-for-growingchanging-brain-metastases-with-same-day-radiation-planning-and-treatment-with-margin-reduction-100603105",false,"NCT07132190","Stereotactic Radiation for Growing\u002FChanging Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction","A Double-Blind Phase II Randomized Study of Adaptively Delivered LINAC-Based Stereotactic Radiation for Volatile Brain Metastases With Same-Day Planning and Margin Reduction","Inclusion Criteria:\n\n1. Participants must have a biopsy proven solid malignancy with at least one intact, residual or recurrent, intracranial lesion radiographically consistent with or pathologically proven to be a brain metastasis meeting one of the following criteria:\n\n   1. Growth of 1.0mm per week or more, on average, based on the two most recent brain MRIs preceding study enrollment\n   2. Abutment, to within 1.0cm, of a region of intracranial edema\n   3. Proximity (within 5.0cm) to a surgical cavity created within 30 days of enrollment\n   4. Proximity (within 5.0cm) to another source of physical displacement\n2. Age of at least 18 years\n3. Karnofsky performance status of at least 60\n4. Estimated survival of at least 3-6 months in the opinion of the enrolling clinician and\u002For study PI\n5. Ability to understand and the willingness to sign a written informed consent document by either ink on paper or a DF\u002FHCC approved eConsent medium\n\nExclusion Criteria:\n\n1. Participants who cannot tolerate a brain MRI\n2. Patients who cannot receive gadolinium\n3. Participants with end stage renal disease\n4. Participants with widespread, definitive leptomeningeal disease\n5. Pregnant women are excluded from this study because of the potential deleterious effects of gadolinium on the developing fetus. Because there is an unknown but potential risk for adverse events in nursing infants, women who are breastfeeding are not eligible for this study as well","ALL","18 Years",{"count":77,"type":78},60,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation treatment. The intent of this shorter time interval is to increase the likelihood that the brain metastases being treated remain fully within the high-dose radiation fields.\n\nParticipants will be randomized to receive brain-directed stereotactic radiation with a 1mm margin or 0mm margin, have their simulation\u002Fradiation planning imaging on the same day that brain-directed stereotactic radiation is delivered, and have repeat simulation\u002Fradiation planning scans during the course of treatment if more than 2-3 days have elapsed since the most recent scans.",[84,85,86,87],"Brain Metastases, Adult","Brain Tumor - Metastatic","Brain Metastases From Non-small Cell Lung Cancer (NSCLC)","Brain Metastases From Extra-cranial Solid Tumors",[89,90,91,92,93,94,25,26,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112],"Brain Mets","Brain Metastases","Brain-directed stereotactic radiation","Brain radiation","Volatile Brain Metastases","Intracranial lesion","RANO","PTV","Planning Target Volume","Local Recurrence","Radiation Necrosis","Adaptive","VMAT","Volumetric Modulated Arc Therapy","Margin","Volatile","Rapid","Growth","Shift","neurocognitive","quality of life","survival","same day","randomized","2026-03-17",{"date":115,"type":116},"2026-03-19","ACTUAL",{"date":118,"type":116},"2025-12-30",{"date":120,"type":78},"2029-09",{"name":61,"class":6},1]